Building on the experience of the GPOH-HD study group since 1978, first and second line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
Phase 1
- Conditions
- Hodgkin's lymphomaTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2006-000995-33-SI
- Lead Sponsor
- Martin Luther University of Halle/Wittenberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 2102
Inclusion Criteria
• diagnosis of classic Hodgkin’s lymphoma
• patient aged under 18 years at time of diagnosis
• written informed consent of the patient and/or the patient’s parents or guardian according to national laws
Are the trial subjects under 18? yes
Number of subjects for this age range: 8
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
pre-treatment of Hodgkin’s lymphoma differing from study protocol (except recommended pre-phase therapy of a large mediastinal tumour) • known hypersensitivity or contraindication to study drugs
• diagnosis of lymphocyte predominant Hodgkin’s lymphoma
• prior chemotherapy or radiotherapy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method